AF
XLO icon

Amalgamated Financial’s Xilio Therapeutics XLO Stock Holding History

Amalgamated Financial’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$8K Buy
+77
New +$12.2K ﹤0.01% 2932

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Amalgamated Financial's XLO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Xilio Therapeutics (XLO) in Q1 2022: 77 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #2932 among its holdings.

41 funds tracked by Wall St. Rank hold XLO as of Q1 2022.

  • Amalgamated Financial held 77 shares of Xilio Therapeutics worth $8K as of Q1 2022.
  • Xilio Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Xilio Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2932 holding.
  • 41 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.